Dyne Therapeutics rises after positive data for its muscle wasting drug

Shares of drug developer Dyne Therapeutics DYN.O rise 16.2% to $23.62

DYN's experimental drug zeleciment rostudirsen for the treatment of Duchenne muscular dystrophy (DMD) met the main goal in an early- to mid-stage trial

In a 32-patient study group that enrolled ambulant and non-ambulant males, those who received the drug produced on average 5.46% of the normal level of dystrophin, a key muscle protein that people with DMD lack

DYN says submission for U.S. accelerated approval is on track for Q2 2026

Including session's move, DYN stock was down 1.3% YTD